Journal
ANNALS OF ONCOLOGY
Volume 24, Issue 10, Pages 2594-2600Publisher
ELSEVIER
DOI: 10.1093/annonc/mdt293
Keywords
lung neoplasm; gene amplification; actinin-4 (ACTN4); prognosis; biomarker
Categories
Funding
- National Institute of Biomedical Innovation (NIBIO) (Osaka, Japan) [10-07, 10-44, 10-45]
- Ministry of Health, Labor and Welfare of Japan (Tokyo, Japan)
- National Cancer Center Research and Development Fund [23-A-11]
- Grants-in-Aid for Scientific Research [25461172, 25670868] Funding Source: KAKEN
Ask authors/readers for more resources
Even if detected at an early stage, a substantial number of lung cancers relapse after curative surgery. However, no method for distinguishing such tumors has yet been established. The copy number of the actinin-4 (ACTN4) gene was determined by fluorescence in situ hybridization on tissue microarrays comprising 543 surgically resected adenocarcinomas of the lung. Amplification (an increase in the copy number by >= 2.0 fold) of the ACTN4 gene was detected in two of seven lung adenocarcinoma cell lines and 79 (15%) of 543 cases of pathological stage I-IV lung adenocarcinoma. Multivariate analysis revealed that ACTN4 gene amplification was the most significant independent factor associated with an extremely high risk of death (hazard ratio, 6.78; P = 9.48 x 10(-5), Cox regression analysis) among 290 patients with stage I lung adenocarcinoma. The prognostic significance of ACTN gene amplification was further validated in three independent cohorts totaling 1033 patients. Amplification of the ACTN4 gene defines a small but substantial subset of patients with stage I lung adenocarcinoma showing a distinct outcome. Such patients require intensive medical attention and might benefit from postoperative adjuvant chemotherapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available